- Home
- FT vs TLSI Comparison
FT vs TLSI Comparison
Compare FT & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FT | TLSI |
|---|---|---|
| Founded | 1988 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 202.6M | 244.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | FT | TLSI |
|---|---|---|
| Price | $7.82 | $7.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.67 |
| AVG Volume (30 Days) | 63.0K | ★ 177.8K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 7.85% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $40,207,000.00 |
| Revenue This Year | N/A | $55.06 |
| Revenue Next Year | N/A | $46.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 49.52 |
| 52 Week Low | $5.97 | $3.42 |
| 52 Week High | $7.23 | $7.70 |
Technical Indicators
Market Signals| Indicator | FT | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 36.80 | 68.06 |
| Support Level | $7.79 | $6.96 |
| Resistance Level | $7.91 | $7.70 |
| Average True Range (ATR) | 0.10 | 0.52 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 12.50 | 75.71 |
Price Performance
Historical ComparisonAbout FT Franklin Universal Trust
Franklin Universal Trust is a closed-end management investment company focused on providing high current income while preserving capital. Its secondary objective is to achieve income growth through dividend increases and capital appreciation. The fund invests in two asset classes: high-yield bonds and utility stocks. It applies fundamental research to build a diversified high-yield bond portfolio and targets utility companies with attractive dividend yields and a history of increasing dividends.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.